Complete remission of multiple myeloma associated IgA pemphigus after therapy with bortezomib (Velcade), cyclophosphamide and dexamethasone: Case report

被引：0
|
作者：
Szturz, P. [1 ,2 ]
Adam, Z. [1 ,2 ]
Feit, J. [1 ,3 ]
Krejci, M. [1 ,2 ]
Pour, L. [1 ,2 ]
Vasku, V. [1 ,4 ]
Cermakova, Z. [5 ]
Hajek, R. [1 ,2 ]
Mayer, J. [1 ,2 ]
机构：
[1] Masaryk Univ, Fac Med, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Internal Med Hematooncol, Brno, Czech Republic
[3] Univ Hosp Brno, Inst Pathol, Brno, Czech Republic
[4] St Annes Univ Hosp Brno, Dept Dermatol & Venereol 1, Brno, Czech Republic
[5] Univ Hosp Brno, Dept Clin Biochem & Hematol, Brno, Czech Republic
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [1] IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen
    Adam, Zdenek
    Krejci, Marta
    Pour, Ludek
    Feit, Josef
    Buechler, Tomas
    Hajek, Roman
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (9-10) : 311 - 314
  • [2] IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimenKomplette Remission von multiplem Myelom und IgA Pemphigus nach Kombinationstherapie mit Bortezomib, Cyclophosphamid und Dexamethason
    Zdenek Adam
    Marta Krejčí
    Luděk Pour
    Josef Feit
    Tomáš Büchler
    Roman Hájek
    Wiener klinische Wochenschrift, 2010, 122 : 311 - 314
  • [3] Cyclophosphamide/dexamethasone/thalidomideWeakness and exacerbation of IgA pemphigus: case report
    Reactions Weekly, 2010, 1316 (1) : 17 - 17
  • [4] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [5] A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
    Bensinger, William
    Jagannath, Sundar
    Vescio, Robert
    Camacho, Elber S.
    Wolf, Jeffrey Lee
    Irwin, David H.
    Capo, Gerardo, III
    McKinley, Marti
    Potts, Phyllis
    Vesole, David H.
    Mazumder, Amitabha
    Esseltine, Dixie-Lee
    Becker, Pamela
    Crowley, John
    Durie, Brian G. M.
    BLOOD, 2008, 112 (11) : 42 - 42
  • [6] Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment
    Szturz, Petr
    Adam, Zdenek
    Vasku, Vladimir
    Feit, Josef
    Krejci, Marta
    Pour, Ludek
    Hajek, Roman
    Mayer, Jiri
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1324 - 1326
  • [7] Complete Remission After Teclistamab Treatment in Multiple Myeloma: Case Report
    Haidar, Nour A.
    Salignon, Karine
    Jounblat, Youssef
    El Jbeili, Mira B.
    Vaillant, Willy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S538 - S539
  • [8] Complete remission achievement during long-term maintenance with bortezomib based therapy in multiple myeloma: A case report
    Crescenzi, Sabrina Leonetti
    Piccioni, Anna Lina
    Bagnato, Antonino
    Venditti, Adriano
    BLOOD, 2007, 110 (11) : 278B - 278B
  • [9] Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
    Kushner, Carolyn J.
    Wang, Shiyu
    Tovanabutra, Napatra
    Tsai, Donald E.
    Werth, Victoria P.
    Payne, Aimee S.
    JAMA DERMATOLOGY, 2019, 155 (12) : 1404 - 1409
  • [10] Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome
    Chim, C. S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 181 - 182
12345